biote Corp.

NASDAQ:BTMD

Medical - Care Facilities

Healthcare
$1.23 +0.22%

+$0.01 today

Market cap
$54.25M
Beta
1.66
P/E (TTM)
4.5
EPS (TTM)
$0.51
52W Low $1.27High $4.75

Volume 0.11M

Average 0.25M

BTMD Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

biote Corp.NASDAQ: BTMD

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $980K rose 14.4% year over year, ahead of the +3.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.0% from the prior quarter. Over 3 fiscal years it compounded at +18.6% a year.

Context

  • Depreciation & amortization amounted to 1.9% of revenue in FY2025, unchanged from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +14.4% holds above the trailing-twelve-month pace of +3.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$980K+3.0% QoQ
Last fiscal yearDec 2025
$3.67M+2.7% YoY
LTMMar 2026
$3.79M+3.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.4%——
1 year+2.7%——
3-year CAGR+18.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
3.67M USD
Year-over-year change
+2.7%
4-year CAGR
+27.2%

Depreciation & Amortization vs competitors

How BTMD compares with its peers on the latest reported figures

  • BTMD's LTM Mar 2026 depreciation & amortization of $3.79M is the 5th largest of the 11 companies compared; the peer median is $2.54M.
  • Its year-over-year change of +3.0% is the 4th highest of 10, against a peer median of -23.0%.
  • Depreciation & amortization amounts to 2.0% of revenue for BTMD, versus a peer median of 12.0%.
BTMD Competitors Peer median
Depreciation & Amortization for BTMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUCDLucid Diagnostics Inc.LTM Mar 2026$429.44M +48315.3%-23.3%8364.7%
SCLXScilex Holding CompanyLTM Mar 2026$6.49M +61.5%+5.3%19.2%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$5.54M -27.5%-26.6%4.8%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$3.84M -23.0%-14.6%334.6%
BTMDbiote Corp.LTM Mar 2026$3.79M +3.0%+18.6%2.0%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$2.99M -3.9%-18.4%—
VORVor Biopharma Inc.LTM Mar 2026$2.09M -38.1%+4.6%—
JYNTThe Joint Corp.LTM Mar 2026$1.71M -54.0%-36.4%3.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$880K +391.6%——
SPROSpero Therapeutics, Inc.LTM Mar 2026$0 -100.0%—0.0%
ACTUActuate Therapeutics IncLTM Mar 2026$0 ———
Peer median (excluding BTMD) $2.54M-23.0%-18.4%12.0%

Competitors are the stored peer set for BTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income32.62M1.32M3.32M46K27.05M
Depreciation & Amortization1.4M2.2M2.99M3.57M3.67M
Deferred Income Tax0(743K)721K(2.9M)3.98M
Stock-Based Compensation082.18M9.06M8.74M8.92M
Change in Working Capital(1.46M)(35.81M)(8.93M)9.93M(8.25M)
Accounts Receivables(752K)(1.56M)(505K)(2.27M)(958K)
Inventory(5.76M)(1.71M)(6.1M)3.71M(6.24M)
Accounts Payables1.61M416K(165K)1.55M1.01M
Other Working Capital3.45M(32.96M)(2.16M)6.94M(2.06M)
Other Non-Cash Items1.16M(58.3M)19.72M25.85M(165K)
Operating Cash Flow33.72M(9.16M)26.88M45.24M35.19M
Capital Expenditures(3.81M)(1.84M)(2.71M)(6.43M)(5.02M)
Acquisitions (Net)000(11.84M)0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(2.36M)(1.51M)(2.35M)(526K)(1.85M)
Investing Cash Flow(3.81M)(1.84M)(2.71M)(18.8M)(6.86M)
Debt Repayment(5M)84.38M(6.25M)(6.25M)(1.25M)
Common Stock Issued0442K144K282K368K
Common Stock Repurchased0(424K)0(5.6M)(3.37M)
Dividends Paid(11.4M)(12.89M)(8.69M)(4.74M)(1.73M)
Other Financing Activities(3.94M)(8.05M)420K(59.77M)(37.58M)
Financing Cash Flow(20.34M)63.46M(14.38M)(76.08M)(43.56M)
Effect of Forex Changes(12K)0(19K)(22K)6K
Net Change in Cash9.56M52.47M9.77M(49.66M)(15.22M)
Free Cash Flow29.91M(11M)24.17M38.81M30.18M

biote Corp.

NASDAQ:BTMD

Intrinsic Alpha fair value

Locked

Current Price

$1.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.